An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade

Published:2021-12 Issue: Volume:101 Page:108307
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Liu Hongchuan,Wang Rui,An Duopeng,Liu Hui,Ye Fan,Li Baoxian,Zhang Jing,Liu Peixiang,Zhang Xuyao,Yao Sheng,Zhong Ziyang,Feng Hui,Feng Meiqing

Funder

Science and Technology Commission of Shanghai Municipality

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference48 articles.

1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy;Sharma;Cell,2017

2. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies;Patel;Immunity,2018

3. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment;Rahimi Kalateh Shah Mohammad;J. Cell. Physiol.,2020

4. Interleukins in cancer: from biology to therapy;Briukhovetska;Nat. Rev. Cancer,2021

5. Interleukin-21: a double-edged sword with therapeutic potential;Spolski;Nat Rev Drug Discov,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and challenges in immunocytokines: A new arsenal against cancer;Acta Pharmaceutica Sinica B;2024-08

2. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview;Pharmaceutics;2024-07-24

3. From bench to bedside: the past, present and future of IL-21 immunotherapy;Medical Oncology;2024-06-20

4. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding;Biomedicine & Pharmacotherapy;2024-06

5. Half‐life extension of single‐domain antibody–drug conjugates by albumin binding moiety enhances antitumor efficacy;MedComm;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3